AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment
02 sept. 2020 16h01 HE
|
AEON Biopharma
-Critical milestone transitions AEON Biopharma to clinical-stage company- -Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021- -Investment expected to provide...